NY-ESO-1 may be a potential target for lung cancer immunotherapy

Cancer Journal from Scientific American

Volumn 5, Issue 1, 1999, Pages 20-25

  Lee, Li ^a   Wang, Rong Fu ^a   Wang, Xiang ^a   Mixon, Arnold ^a   Johnson, Bruce E ^a   Rosenberg, Steven A ^a   Schrump, David S ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

5 aza 2' deoxycytidine; Demethylation; Lung cancer; NY ESO 1; Tumor antigen; Tumor immunology

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; TUMOR ANTIGEN;

ANTIGEN RECOGNITION; ANTIGEN SPECIFICITY; ARTICLE; CANCER CELL CULTURE; CANCER IMMUNOTHERAPY; DRUG TARGETING; ESOPHAGUS CANCER; HLA TYPING; HUMAN; HUMAN CELL; LUNG CANCER; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; TRANSCRIPTION REGULATION;

ANTIGENS, NEOPLASM; CANCER VACCINES; CARCINOMA, SMALL CELL; ESOPHAGEAL NEOPLASMS; HLA-A ANTIGENS; HUMANS; LUNG NEOPLASMS; MEMBRANE PROTEINS; PROTEIN BIOSYNTHESIS; PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; T-LYMPHOCYTES, CYTOTOXIC; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 0033008444     PISSN: 10814442     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Van den Eynde BJ, van der Bruggen P. T cell defined tumor antigens. Curr Opin Immunol 1997;9:684-693.
2. Kawakami Y, Rosenberg SA. Human tumor antigens recognized by T-cells. Immunol Res 1997;16:313-339.
3. Chen Y-T, Scanlan MJ, Sahin U et al. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Nad Acad Sci USA 1997;94:1914-1918.
4. Sahin U, Türeci Ö, Schmitt H et al. Human neoplasms elicit multiple specific immune responses in the autologous host. Proc Nad Acad Sci USA 1995; 92:11810-11813.
5. Sahin U, Türeci Ö, Pfreundschuh M. Serological identification of human tumor antigens. Curr Opin Immunol 1997;9:709-716.
6. Jager E, Chen Y-T, Drijfhout JW et al. Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes. J Exp Med 1998;187:265-270.
7. Wang R-F, Johnston S, Zeng G et al. A breast and melanoma shared tumor antigen: T cell responses to antigenic peptides translated from different open reading frames. J Immunol 1998;161:3596-3606.
8. Itoh K, Hayashi A, Toh Y et al. Development of cancer vaccine by tumor rejection antigens. Intern Rev Immunol 1997;14:153-171.
9. Marincola FM, Shamamian P, Alexander RB et al. Loss of HLA haplotype and B locus down-regulation in melanoma cell lines. J Tumor Immunol 1994;153:1225-1237.
10. Weber J, Salgaller M, Damid D et al. Expression of the MAGE-1 tumor antigen is up-regulated by the demethylating agent 5-aza-2′-deoxycytidine. Cancer Res 1994;54:1766-1771.
11. Serrano A, García A, Abril E et al. Methylated CpG points identified within MAGE-1 promoter are involved in gene repression. Int J Cancer 1996;68:464-470.
12. Wang R-F, Wang X, Johnston SL et al. Development of a retroviral-based cDNA expression system for the cloning of tumor antigens. Cancer Res 1998;58:3519-3525.
13. De Smet C, De Backer O, Faraoni I et al. The activation of human gene MAGE-1 in tumor cells is correlated with genome-wide demethylation. Proc Nad Acad Sci USA 1996;93:7149-7153.
14. Kimura H, Yamaguchi Y. Adjuvant immunotherapy with interleukin 2 and lymphokine-activated killer cells after noncurative resection of primary lung cancer. Lung Cancer 1995;13:31-44.
15. Kimura H, Yamaguchi Y. Adjuvant chemo-immunotherapy after curative resection of Stage II and IIIA primary lung cancer. Lung Cancer 1996;14:301-314.
16. Ratto GB, Zino P, Mirabelli S et al. A randomized trial of adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 versus standard therapy in the postoperative treatment of resected nonsmall cell lung cancer carcinoma. Cancer 1998;78:244-251.
17. Zocchi M, Ferrarini M, Migone N et al: T-cell receptor VΔ gene usage by tumour reactive VΔ T lymphocytes infiltrating human lung cancer. Immunology 1994;81:234-239.
18. M4g, from a patient with lung cancer. Cancer Res 1998;52:2292-2297.
19. Slingluff CL Jr, Cox AL, Stover JM Jr et al. Cytotoxic T-lymphocyte response to autologous human squamous cell cancer of the lung: epitope reconstitution with peptides extracted from HLA-Aw68. Cancer Res 1994;54:2731-2737.
20. Seki N, Hoshino T, Kikuchi M et al. HLA-A locus-restricted and tumor-specific CTLs in tumor-infiltrating lymphocytes of patients with non-small cell lung cancer. Cell Immunol 1997;175:101-110.
21. Haas GJ, D'Cruz O, DeBault L. Distribution of human leukocyte antigen-ABC and -D/DR antigens in the unfixed human testis. Am J Reprod Immunol Microbiol 1988;18:47-51.
22. Gaugler B, Van den Eynde B, van der Bruggen P et al. Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes. Exp Med 1994;179:921-930.
23. van der Bruggen P, Bastin J, Gajewski T et al. A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3. Eur J Immunol 1994;24:3038-3043.
24. Visseren MJ, van der Burg SH, van der Voort EI et al. Identification of HLA-A*0201-restricted CTL epitopes encoded by the tumor-specific MAGE-2 gene product. Int J Cancer 1997;73:125-130.
25. Marchand M, Weynants P, Rankin E et al. Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGE-3 [letter]. Int J Cancer 1995;63:883-885.
26. Sakata M. Expression of MAGE gene family in lung cancers. Kurume Med J 1996;43:55-61.
27. Weynants P, Lethé B, Brasseur F et al. Expression of MAGE genes by non-small-cell lung carcinomas. Int J Cancer 1994;56:826-829.
28. Traversari C, Meazza R, Coppolecchia M et al. IFN-γ gene transfer restores HLA-class I expression and MAGE-3 antigen presentation to CTL in HLA-deficient small cell lung cancer. Gene Ther 1997;4:1029-1035.
29. Doyle A, Martin JW, Funa K et al. Markedly decreased expression of class I histocompatibility antigens, protein, and mRNA in human small-cell lung cancer. J Exp Med 1985;161:1135-1151.
30. Restifo NP, Esquivel F, Kawakami Y et al. Identification of human cancers deficient in antigen processing. J Exp Med 1993;177:265-272.
31. Singal DP, Ye M, Qiu X. Molecular basis for lack of expression of HLA class I antigens in human small-cell lung carcinoma cell lines. Int J Cancer 1996;68:629-636.